Outset Medical, Inc. (OM) - Form 8-K Summary
Business Context and Reporting Period
This Form 8-K was filed by Outset Medical, Inc. on September 23, 2024. The report addresses a regulatory notice received from The Nasdaq Stock Market LLC regarding the continued listing of the Company's common stock on the Nasdaq Global Select Market.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. The only financial metric disclosed is the stock price performance triggering the listing notice: the closing bid price fell below $1.00 per share for 30 consecutive trading days.
Material Changes
The material change reported is the Company's failure to meet the minimum bid price requirement under Nasdaq Listing Rule 5450(a)(1). This deficiency is based on the stock price remaining below $1.00 per share for the preceding 30 trading days.
Outlook, Risks, and Contingencies
- Compliance Period: The Company has been granted an initial 180-day compliance period ending March 24, 2025, to regain compliance.
- Remediation Requirement: To cure the deficiency, the closing bid price must meet or exceed $1.00 per share for at least 10 consecutive trading days before the March 24, 2025 deadline.
- Delisting Risk: If compliance is not achieved by the deadline, the Company may be eligible for an additional 180-day period only if it applies to transfer listing to the Nasdaq Capital Market and meets specific market value and listing standards.
- Uncertainty: Management states there can be no assurance that the Company will regain compliance or avoid delisting. If delisting is determined, the Company retains the right to appeal, during which time the stock would remain listed.
Key Facts for Investor Verification
- Verify the current trading price of OM stock relative to the $1.00 threshold.
- Monitor the Company's progress toward achieving 10 consecutive days of trading above $1.00 before March 24, 2025.
- Check for any future announcements regarding an application to transfer listing to the Nasdaq Capital Market if the initial compliance period expires without a cure.
- Review the Company's broader financial health in subsequent filings (10-Q/10-K) as this 8-K does not contain operational financial data.